David Gindler is head of Milbank’s Intellectual Property Litigation and Licensing Group. Recognised in Chambers USA as Band 1 for Life Sciences: IP/Patent Litigation in California, Gindler’s work spans a broad array of technologies including biosimilars, diagnostic tests, medical devices, and advanced research tools. He has achieved extraordinary trial outcomes for both plaintiffs and defendants, including a $302 million jury verdict for breach of a research and license agreement, as well as defeating a $217 million damages claim where liability had already been established in an earlier trial handled by a different law firm.